Physician

Jose A Bufill, M.D.

According to 2025 Medicare claims, Jose Bufill, M.D. (NPI: 1558365031) practices medical oncology in the South Bend-Mishawaka, IN-MI market, with the plurality of this provider's patient population coming from St. Joseph, IN. This provider's primary affiliated billing organization is MICHIANA HEMATOLOGY-ONCOLOGY P C (NPI: 1619970183; TIN: 351686054) and primary practice location at 46545-1470. Bufill is affiliated with the CHA ACO, LLC (ACO ID: A2207), participating under the MSSP model.

Bufill's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 641 traditional Medicare patients, billed 100,994 HCPCS/CPT codes, and received $1,339,230 in Medicare payments. The top billing code was 74177 (Ct scan of abdomen and pelvis with contrast). Part D data shows 1,666 prescription claims across 259 beneficiaries totaling $6,962,837 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 23 claims. Open Payments data shows 14 records totaling $302. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $2,840,293 to $1,339,230. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,589,405 to $6,962,837. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $9,331 to $1,545.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	909	228,875	$2,840,293
2016	879	351,192	$3,881,021
2017	990	365,438	$4,417,522
2018	1,017	469,508	$6,007,475
2019	1,135	608,641	$8,835,046
2020	914	338,985	$5,321,001
2021	824	293,222	$4,951,456
2022	735	215,746	$4,791,442
2023	690	161,690	$2,711,769
2024	641	100,994	$1,339,230

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	248	1,716	$2,589,405
2016	218	1,591	$2,637,291
2017	206	1,726	$2,843,325
2018	229	1,371	$2,332,520
2019	242	1,511	$2,762,603
2020	254	1,910	$4,247,206
2021	249	2,011	$5,669,900
2022	284	1,686	$5,618,548
2023	249	1,531	$5,668,397
2024	259	1,666	$6,962,837

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	24	133	$34,385
2016	15	71	$5,884
2017	15	18	$1,532
2018	N/R	N/R	N/R
2019	11	13	$1,198
2020	N/R	N/R	N/R
2021	N/R	61	$3,205
2022	N/R	46	$2,131
2023	11	45	$3,026
2024	N/R	23	$2,027

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
74177	Ct scan of abdomen and pelvis with contrast	89	100	$160
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	247	633	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	285	456	$62
71260	Ct scan of chest with contrast	99	107	$46
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	117	13,090	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	74	2,152	$1,217,502
Pomalyst	Pomalidomide	59	1,641	$1,090,787
Revlimid	Lenalidomide	51	1,428	$982,969
Xtandi	Enzalutamide	42	1,260	$581,875
Venclexta	Venetoclax	57	1,660	$487,900

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	12	$1,291
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	11	$736

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	14	$302	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jose A. Bufill, M.D.?

Tedicare shows public-source Medicare data for Jose A. Bufill, M.D. (NPI 1558365031), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jose A. Bufill, M.D. have ACO affiliation data?

Jose A. Bufill, M.D. is shown with ACO affiliation data for CHA ACO, LLC (MSSP, ACO ID A2207).

What billing organization is linked to Jose A. Bufill, M.D.?

Jose A. Bufill, M.D. is linked to MICHIANA HEMATOLOGY-ONCOLOGY P C (billing NPI 1619970183) in the available physician profile data.

Does Jose A. Bufill, M.D. have Open Payments data?

Jose A. Bufill, M.D. has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.